Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial investigating BR790 in combination with Anlotinib for adults with advanced non-small cell lung cancer in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating nivolumab, cabozantinib S-malate, and ipilimumab in recurrent stage IV non-small cell lung cancer has completed wit…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer [Phase 1]
Phase 1 trial of DS-1205c with gefitinib in EGFR-mutant metastatic or unresectable non-small cell lung cancer was terminated; results posted…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC [Phase 3]
A Phase 3 trial evaluating toripalimab with chemotherapy versus placebo with chemotherapy in treatment-naive advanced non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 study of GEN1044 (DuoBody-CD3x5T4) in malignant solid tumors has been terminated with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing mil60 to bevacizumab in treatment-naïve non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors [Phase 1]
Phase 1 study evaluating drug-drug interaction between brigatinib and midazolam in ALK+ or ROS1+ solid tumors completed with posted results …
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases [Phase 1]
Phase 1 open-label trial investigating [11C]Osimertinib in EGFR-mutant NSCLC with brain metastases; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: Lazertinib 160mg in EGFR T790M NSCLC [Phase 2]
Phase 2 clinical trial update for lazertinib 160mg in EGFR T790M non-small cell lung cancer (Stage IV).
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors [Phase 2]
Phase 2 trial evaluating brigatinib after treatment with next-generation ALK inhibitors in non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC [Phase 2]
Phase 2 trial evaluating SBRT and oncolytic virus therapy prior to pembrolizumab in metastatic non-small cell lung cancer and metastatic tri…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC [Phase 1, Phase 2]
Trial update for HS-10296 in non-small cell lung cancer across Phase 1 and Phase 2 evaluating safety, PK, and efficacy.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients [Phase 3]
Phase 3 trial evaluating HS-10296 as first-line treatment for non-small cell lung cancer. Status and results are not provided in the snippet…
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 [Phase 2]
Phase 2 platform trial update comparing novel regimens against standard of care in non-small cell lung cancer; trial completed with results …
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients [Phase 3]
Phase 3 trial evaluating Exparel and Marcaine for pain management in thoracoscopic lobectomy; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） [Phase 2]
Phase 2 clinical trial update for Utidelone Injection in patients with advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) [Phase 2]
Phase 2 trial results for talazoparib plus avelumab in STK11-mutant stage IV non-small cell lung cancer (LUNG-MAP trial) have been completed…
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 trial investigating serplulimab combined with an anti-VEGF antibody in advanced lung adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC [Phase 2]
Phase 2 trial investigating furmonertinib combined with anlotinib as first-line therapy for EGFR mutation-positive non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Avelumab in First-line NSCLC (JAVELIN Lung 100) [Phase 3]
A Phase 3 trial evaluating first-line avelumab in non-small cell lung cancer has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC [Phase 2]
Phase 2 trial investigating optimal sequencing of pembrolizumab and platinum-based chemotherapy as first-line treatment for non-small cell l…
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI [Phase 3]
Phase 3 trial evaluating toripalimab plus pemetrexed and platinum in advanced non-small cell lung cancer previously treated with EGFR-TKI.
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy [Phase 2]
Phase 2 trial investigating almonertinib in non-small cell lung cancer patients with abnormal liver function after EGFR-TKI treatment or as …
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Evaluation of GLR2007 for Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating GLR2007 for advanced solid tumors has completed.